enVVeno Medical Wins FDA IDE for TAVVE Trial

enVVeno Medical ( (NVNO) ) just unveiled an update.

On April 29, 2026, enVVeno Medical announced that the U.S. Food and Drug Administration granted its first-ever Investigational Device Exemption approval for a U.S. pivotal study of a non-surgical replacement venous valve, clearing the company to begin the Transcatheter Venous Valve Endoprosthesis (TAVVE) trial of its minimally invasive enVVe System in patients with severe deep Chronic Venous Insufficiency. The two-stage study will start later in 2026 with an initial 10-patient safety cohort, followed by a 220-patient randomized phase at up to 40 U.S. sites, and one year after the last patient in the second stage is enrolled the company could become eligible to seek FDA post-marketing approval.

enVVeno said the IDE approval positions it to pursue what could become the first effective treatment for approximately 3 million U.S. patients with severe deep CVI, a condition that currently lacks viable therapies despite imposing an estimated $20 billion annual burden on the healthcare system. The company also disclosed that as of March 31, 2026, it held about $25 million in cash and investments, which management expects will fund operations into the third quarter of 2027, providing a runway to execute the pivotal trial and potentially strengthen its competitive position in the emerging market for venous valve interventions.

Spark’s Take on NVNO Stock

According to Spark, TipRanks’ AI Analyst, NVNO is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, recurring losses, and persistent negative free cash flow), alongside a technically pressured price trend below key moving averages. Valuation is also challenged by a negative P/E and no dividend support. Offsetting these, corporate news is constructive with regained Nasdaq compliance and reported cash/investments supporting near-term execution.

To see Spark’s full report on NVNO stock, click here.

More about enVVeno Medical

enVVeno Medical Corporation is an Irvine, California-based, clinical-stage medical device company focused on developing innovative bioprosthetic solutions for deep venous disease. Its lead product, the minimally invasive enVVe System, is a first-in-class, transcatheter, non-surgical replacement venous valve designed to treat severe deep Chronic Venous Insufficiency in a large, currently underserved patient population.

enVVe is engineered as a one-way valve to help propel blood up the leg to the heart and lungs, using a self-expanding nickel-titanium frame, multiple valve sizes and a mono-cusp leaflet cut from porcine pericardium. The device is delivered via a small-profile, over-the-wire system intended for use under light sedation without an overnight hospital stay, aiming to raise the standard of care in deep venous disease.

Average Trading Volume: 16,008

Technical Sentiment Signal: Sell

Current Market Cap: $7.81M

For an in-depth examination of NVNO stock, go to TipRanks’ Overview page.